Changjiang Pharmaceuticals: Revenue of 1.2-1.7 billion yuan by 2025, company may be delisted.

The Yangtze River Pharmaceutical announced that it is expected to have an operating income of 1.2-1.7 billion yuan by 2025, an increase from the 1.12 billion yuan of the previous year. The net profit attributable to shareholders of the listed company is expected to have a loss of 3.5-5.2 billion yuan, compared to a loss of 6.28 billion yuan in the previous year. The net assets at the end of the period are expected to be -6 to -9 billion yuan, compared to -4.33 billion yuan at the end of the previous year. The performance change is due to the provision for credit impairment losses of about 4 billion yuan and the impact of the administrative penalty notice. In addition, the company's stock may be delisted due to trading, financial, or major illegal reasons, and seven subsidiaries including Changjiang Xing will change their bankruptcy administrators, with Yiheng Technology expected to stop production in the long term.